Heat waves against cancer: new trial tests hyperthermia for rectal tumors

NCT ID NCT07372300

Recruiting now Disease control Sponsor: Shih-Kai Hung Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether adding modulated electro-hyperthermia (mEHT) to standard treatment helps shrink locally advanced rectal cancer. About 126 adults will receive either standard therapy alone or with mEHT twice a week for six weeks. The goal is to see if the heat-based treatment improves tumor down-staging and complete response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: modulated electro-hyperthermia (mEHT) using the Oncotherm EHY-2030 device
What this could lead to: If it works, this could offer a way to shrink rectal tumors more effectively before surgery, potentially improving outcomes and reducing recurrence.
What could go wrong: This is a mid-stage trial with only 126 participants, so results may not apply broadly. The added hyperthermia could cause discomfort or skin burns, and it may not improve response over standard therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hyperthermia rectal carcinoma rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED RECTAL CARCINOMA

Contacts and locations

Locations

Dalin Tzu Chi Hospital
RECRUITING

Chiayi City, Dalin Township, 600401, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.